Serum level of soluble interleukin-2 receptor correlates with CD25 expression in patients with T lymphoblastic lymphoma

Tomohiro Toji, Katsuyoshi Takata, Yasuharu Sato, Tomoko Miyata-Takata, Eiko Hayashi, Toshiyuki Habara, Yoshinobu Maeda, Mitsune Tanimoto, Tadashi Yoshino

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Acute lymphoblastic leukaemia/lymphoma (ALL/LBL) is an aggressive form of non-Hodgkin's lymphoma (NHL) affecting B-cells or T-cells, respectively. The serum level of soluble interleukin-2 receptor (sIL-2R) is known to reflect the immune activity and tumour volume in aggressive NHL; however, the release of sIL-2R in LBL has not been extensively studied. Further, the relationship between sIL-2R release and the expression level of IL-2R α subunit (CD25) remains unknown. In the present study, we examined the serum level of sIL-2R in 23 patients with T lymphoblactic lymphoma (T-LBL) and compared these with the levels in 20 patient with T acute lymphoblastic leukaemia (T-ALL), 40 patients with diffuse large B-cell lymphoma (DLBCL) and 40 patients with peripheral T-cell lymphoma (PTCL), not otherwise specified. The release of sIL-2R into the serum in patients with T-LBL was significantly lower than that for T-ALL, DLBCL and PTCL (p

Original languageEnglish
Pages (from-to)622-627
Number of pages6
JournalJournal of Clinical Pathology
Volume68
Issue number8
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Interleukin-2 Receptors
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Peripheral T-Cell Lymphoma
Serum
Lymphoma, Large B-Cell, Diffuse
Non-Hodgkin's Lymphoma
Lymphoma
Tumor Burden
B-Lymphocytes
T-Lymphocytes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Serum level of soluble interleukin-2 receptor correlates with CD25 expression in patients with T lymphoblastic lymphoma. / Toji, Tomohiro; Takata, Katsuyoshi; Sato, Yasuharu; Miyata-Takata, Tomoko; Hayashi, Eiko; Habara, Toshiyuki; Maeda, Yoshinobu; Tanimoto, Mitsune; Yoshino, Tadashi.

In: Journal of Clinical Pathology, Vol. 68, No. 8, 01.08.2015, p. 622-627.

Research output: Contribution to journalArticle

Toji, Tomohiro ; Takata, Katsuyoshi ; Sato, Yasuharu ; Miyata-Takata, Tomoko ; Hayashi, Eiko ; Habara, Toshiyuki ; Maeda, Yoshinobu ; Tanimoto, Mitsune ; Yoshino, Tadashi. / Serum level of soluble interleukin-2 receptor correlates with CD25 expression in patients with T lymphoblastic lymphoma. In: Journal of Clinical Pathology. 2015 ; Vol. 68, No. 8. pp. 622-627.
@article{570ca08ec91b48debc707a74ff62808d,
title = "Serum level of soluble interleukin-2 receptor correlates with CD25 expression in patients with T lymphoblastic lymphoma",
abstract = "Acute lymphoblastic leukaemia/lymphoma (ALL/LBL) is an aggressive form of non-Hodgkin's lymphoma (NHL) affecting B-cells or T-cells, respectively. The serum level of soluble interleukin-2 receptor (sIL-2R) is known to reflect the immune activity and tumour volume in aggressive NHL; however, the release of sIL-2R in LBL has not been extensively studied. Further, the relationship between sIL-2R release and the expression level of IL-2R α subunit (CD25) remains unknown. In the present study, we examined the serum level of sIL-2R in 23 patients with T lymphoblactic lymphoma (T-LBL) and compared these with the levels in 20 patient with T acute lymphoblastic leukaemia (T-ALL), 40 patients with diffuse large B-cell lymphoma (DLBCL) and 40 patients with peripheral T-cell lymphoma (PTCL), not otherwise specified. The release of sIL-2R into the serum in patients with T-LBL was significantly lower than that for T-ALL, DLBCL and PTCL (p",
author = "Tomohiro Toji and Katsuyoshi Takata and Yasuharu Sato and Tomoko Miyata-Takata and Eiko Hayashi and Toshiyuki Habara and Yoshinobu Maeda and Mitsune Tanimoto and Tadashi Yoshino",
year = "2015",
month = "8",
day = "1",
doi = "10.1136/jclinpath-2015-202934",
language = "English",
volume = "68",
pages = "622--627",
journal = "Journal of Clinical Pathology - Clinical Molecular Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Serum level of soluble interleukin-2 receptor correlates with CD25 expression in patients with T lymphoblastic lymphoma

AU - Toji, Tomohiro

AU - Takata, Katsuyoshi

AU - Sato, Yasuharu

AU - Miyata-Takata, Tomoko

AU - Hayashi, Eiko

AU - Habara, Toshiyuki

AU - Maeda, Yoshinobu

AU - Tanimoto, Mitsune

AU - Yoshino, Tadashi

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Acute lymphoblastic leukaemia/lymphoma (ALL/LBL) is an aggressive form of non-Hodgkin's lymphoma (NHL) affecting B-cells or T-cells, respectively. The serum level of soluble interleukin-2 receptor (sIL-2R) is known to reflect the immune activity and tumour volume in aggressive NHL; however, the release of sIL-2R in LBL has not been extensively studied. Further, the relationship between sIL-2R release and the expression level of IL-2R α subunit (CD25) remains unknown. In the present study, we examined the serum level of sIL-2R in 23 patients with T lymphoblactic lymphoma (T-LBL) and compared these with the levels in 20 patient with T acute lymphoblastic leukaemia (T-ALL), 40 patients with diffuse large B-cell lymphoma (DLBCL) and 40 patients with peripheral T-cell lymphoma (PTCL), not otherwise specified. The release of sIL-2R into the serum in patients with T-LBL was significantly lower than that for T-ALL, DLBCL and PTCL (p

AB - Acute lymphoblastic leukaemia/lymphoma (ALL/LBL) is an aggressive form of non-Hodgkin's lymphoma (NHL) affecting B-cells or T-cells, respectively. The serum level of soluble interleukin-2 receptor (sIL-2R) is known to reflect the immune activity and tumour volume in aggressive NHL; however, the release of sIL-2R in LBL has not been extensively studied. Further, the relationship between sIL-2R release and the expression level of IL-2R α subunit (CD25) remains unknown. In the present study, we examined the serum level of sIL-2R in 23 patients with T lymphoblactic lymphoma (T-LBL) and compared these with the levels in 20 patient with T acute lymphoblastic leukaemia (T-ALL), 40 patients with diffuse large B-cell lymphoma (DLBCL) and 40 patients with peripheral T-cell lymphoma (PTCL), not otherwise specified. The release of sIL-2R into the serum in patients with T-LBL was significantly lower than that for T-ALL, DLBCL and PTCL (p

UR - http://www.scopus.com/inward/record.url?scp=84937970136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937970136&partnerID=8YFLogxK

U2 - 10.1136/jclinpath-2015-202934

DO - 10.1136/jclinpath-2015-202934

M3 - Article

C2 - 25935549

AN - SCOPUS:84937970136

VL - 68

SP - 622

EP - 627

JO - Journal of Clinical Pathology - Clinical Molecular Pathology

JF - Journal of Clinical Pathology - Clinical Molecular Pathology

SN - 0021-9746

IS - 8

ER -